Project Grant K08CA290062
Award Date
8/20/25
Completion Date
7/31/30
Dollars Obligated
$271K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $282,053, effective March 1, 2025 through February 28, 2030, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award supports research by Dr. Keenan at the University of California, San Francisco (UCSF) to investigate mechanisms of resistance to immunotherapy in hepatocellular carcinoma (HCC), a primary liver cancer. The key objectives are to: 1) examine the role of immunosuppressive myeloid...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer or hepatocellular carcinoma (HCC) during HIV infection and immunotherapy. The key objectives are to: Investigate how TAPDC reprogram the HCC tumor immune microenvironment, and how HIV infection affects TAPDC/tumor...
This $1,224,644 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to dissect a novel tumor-promoting axis in intrahepatic cholangiocarcinoma (ICCA), a highly desmoplastic and deadly form of bile duct cancer. The research, conducted by the Icahn School of Medicine at Mount Sinai, leverages preliminary data suggesting that the immune checkpoint protein B7-H4 plays a critical role in ICCA tumor growth and desmoplastic reaction through its...
This federal Project Grant award of $145,336 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to metabolically reprogram hepatic macrophages to overcome immune evasion in "immune-desert" tumors driven by B-catenin activation. The research aims to determine how deleting the mTORC1 suppressor TSC1 in hepatic macrophages can enhance their antigen-presenting capabilities and promote CD8+ T cell-mediated cancer immunity in a murine model of...
This Project Grant award, identified as K22CA288784, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to the University of Massachusetts Medical School (UMass Medical) to support research aimed at "Deciphering the Immune Evasion Mechanisms in Mutant IDH1 Cancer." The $196,029 award will fund a 3-year project (4/1/2025 - 3/31/2028) to elucidate the mechanisms by which mutations in the IDH1 gene create an immunosuppressive tumor microenvironment in...
This federal Project Grant award, with ID K08CA286847, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $171,135 grant will support Dr. Resmi Charalel's research and training to develop a multi-level intervention to improve access to treatment for patients with small hepatocellular carcinoma (HCC). The key objectives are to: 1) identify barriers and facilitators to timely treatment for small HCC patients using qualitative...
This federal Project Grant award, with an ID of R01CA294704, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic for the project "Radiation and Dendritic Cell Combination to Improve Immunotherapy Response in Intrahepatic Cholangiocarcinoma". The $610,890 award, effective September 1, 2024 through August 31, 2029, will support a two-part research study. The first aim is to assess the clinical efficacy of combining external beam...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $139,247 to the University of Texas MD Anderson Cancer Center to conduct research on using an antibody-drug conjugate (CD47-LLO) to promote antitumor immune responses against cancers that produce high levels of extrachromosomal DNA (ecdna). The key objectives of the research are to: 1) mechanistically examine how ecdna detection in antigen-presenting cells triggers antitumor signaling...
The National Cancer Institute (NCI) awarded a 5-year, $678,515 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The University of Texas MD Anderson Cancer Center to evaluate the use of 18F-FSPG PET imaging and liquid biopsy (circulating tumor DNA) to predict response and detect recurrence in hepatocellular carcinoma (liver cancer) patients treated with yttrium-90 radioembolization therapy. The project aims to determine if 18F-FSPG PET can identify treatment-resistant...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...